Kiran Dallenbach

Kiran Dallenbach is an Investment Manager at BioMedPartners, Basel (Switzerland), which she joined in 2019 with a background in venture capital and life sciences. She currently serves as a Board Member for Azafaros, as a Board Observer for ImmunOs Therapeutics and is leading the management of BioMed’s public equities.

Prior to BioMedPartners, Kiran was an Investment Analyst at Redalpine Venture Partners, a venture capital firm focusing on European early-stage life science and technology companies. As part of an emerging venture fund, she was involved in all aspects of the business, ranging from healthcare investments and company creation to fund strategy and growth. Previously, she was a researcher in the department of Immunotherapeutics at Cytos Biotechnology, focused on pre-clinical projects in the field of inflammatory autoimmune diseases.

Kiran holds a PhD in Immunology and a MSc degree in Biotechnology from the Swiss Federal Institute of Technology Zurich (ETHZ).